In the article titled "Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-*κ*B Pathway in Type 2 Diabetic db/db Mice" \[[@B1]\], in Figure 3(c)(A), the value of ordinate should be narrowed down to 0.01 times that of the data presented. And in Figure 6(b), the abscissa p-65/p65 should be changed to p-p65/p65. The two corrected figures are presented here.

![Irb alleviated diabetes-induced podocyte injury and the thickening of the GBM. (a) Representative fields of podocyte foot processes under TEM (scale bars: 2 *μ*m; red arrow indicates podocyte foot process effacement). (b) Representative fields of nephrin, as labeled by immunohistochemical staining (scale bars: 50 *μ*m). (c) Quantification of the GBM thickness (A) and immunohistochemical staining (B). The bars in panel (c) show the mean expression in arbitrary units (error bars, SD). ^*∗*^ *P* \< 0.05 compared with db/m; ^\#^ *P* \< 0.05 compared with db/db, *t*-test.](MI2016-3151986.001){#fig1}

![Irb inhibited NF-*κ*B pathway activation in db/db mice. (a) Representative immunoblot of p-I*κ*B*α*, I*κ*B*α*, p-p65, and p65 in the kidney. (b) Quantification of the immunoblot: the ratio between p-I*κ*B*α* and I*κ*B*α* and the ratio between p-p65 and p65 are presented. The bars in panel (b) show the mean expression in arbitrary units (error bars, SD). ^*∗*^ *P* \< 0.05 compared with db/m; ^\#^ *P* \< 0.05 compared with db/db, *t*-test.](MI2016-3151986.002){#fig2}
